RecruitingPhase 2NCT04305691
Trial of Ixazomib for Kaposi Sarcoma
Studying Kaposi sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AIDS Malignancy Consortium
- Principal Investigator
- Erin Reid, MDAIDS Malignancy Consortium
- Intervention
- Ixazomib Citrate(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (10)
- UC San Diego, San Diego, California, United States
- Zuckerberg San Francisco General Hospital, San Francisco, California, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Washington University, St Louis, Missouri, United States
- Mount Sinai Hospital, New York, New York, United States
- Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
- Thomas Street Clinic, Houston, Texas, United States
- Virginia Mason Medical Center, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04305691 on ClinicalTrials.govOther trials for Kaposi sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06445166Propranolol for the Treatment of Kaposi Sarcoma in AdultsWashington University School of Medicine
- RECRUITINGNCT06751355Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility TrialWashington University School of Medicine
- RECRUITINGNCT06375122Natural History Study of Kaposi SarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE1NCT05646082Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi SarcomaImperial College London
- ACTIVE NOT RECRUITINGPHASE2NCT04577755Pomalidomide Treatment in Patients With Kaposi SarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT04742387Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal AnalysisNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT03993106A Study of sEphB4-HSA in Kaposi SarcomaVasgene Therapeutics, Inc
- RECRUITINGPHASE1, PHASE2NCT04303117PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi SarcomaNational Cancer Institute (NCI)